Related Experiment Videos

Naltrexone suppresses the rejection of cardiac tissue transplantation

Y F Li1, J X Wang, L Shao

  • 1Department of Physiology, Beijing Medical University, China.

Insights

Transplanted cardiac tissue is rejected by the host within 9 days. Naltrexone, an opiate antagonist, extended survival to 13 days, indicating opioid signaling

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Biology

Background:

  • Cardiac tissue transplantation triggers an inflammatory response leading to host rejection.
  • Opioid signaling molecules are implicated in the complex mechanisms of immune response and tissue survival.

Purpose of the Study:

  • To investigate the role of endogenous opioid signals in the immune response to cardiac allografts.
  • To determine the effect of naltrexone on the survival of transplanted cardiac tissue.
  • To explore the impact of naltrexone on lymphocyte proliferation and DNA synthesis.

Main Methods:

  • Cardiac tissue transplantation in a murine model.
  • Administration of naltrexone (opiate antagonist) and mitomycin C (DNA synthesis inhibitor).
  • Assessment of tissue survival time and lymphocyte proliferative response using assays like concanavalin A stimulation.

Main Results:

  • Cardiac allograft survival was significantly extended from 9 to 13 days with naltrexone treatment.
  • Naltrexone and mitomycin C both reduced lymphocyte proliferative responses in mixed lymphocyte populations.
  • Naltrexone administration suppressed spleen lymphocyte proliferation in concanavalin A-stimulated mice.

Conclusions:

  • Endogenous opioid signals play a crucial role in activating immunocytes and stimulating DNA synthesis.
  • Naltrexone demonstrates immunomodulatory effects, impacting both tissue rejection and lymphocyte activation.
  • Targeting opioid signaling pathways may offer novel therapeutic strategies for enhancing transplant survival.

Related Concept Videos